^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Basal Cell Carcinoma

    Related cancers:
    2d
    A Study on Radiation Therapy Guided by the Reflectance Confocal Microscopy (RCM)/Optical Coherence Tomography (OCT) Device in People With Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=38, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    5d
    Prenatal detection of Gorlin-Goltz syndrome: a case report and focused review of the literature. (PubMed, Front Med (Lausanne))
    Close interdisciplinary teamwork between prenatal ultrasound specialists and geneticists is essential to correctly evaluate non-specific fetal abnormalities and establish an accurate diagnosis in the fetus. Sometimes, as in this case, this process can lead to the reclassification of known genetic variants or even the identification of novel variants.
    Journal
    |
    PTCH1 (Patched 1)
    8d
    Metastatic Basal Cell Carcinoma With Unusual Molecular Genetics Findings. (PubMed, Clin Case Rep)
    The patient was managed with complete excision of the lesion, along with a neck dissection for level V lymph nodes, and adjuvant chemotherapy with Vismodegib...However, considering the possibility of metastasis, the patient is being followed up by a multi-disciplinary team (MDT) for evaluation of level IIB cervical lymph nodes. This case highlights the diagnostic and therapeutic challenges that may arise in rare cases of BCC with metastasis.
    Journal
    |
    CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • HMGA2 (High mobility group AT-hook 2)
    |
    Erivedge (vismodegib)
    8d
    Active Surveillance for the Treatment of Low-Risk Basal Cell Carcinoma in Elderly Patients (clinicaltrials.gov)
    P=N/A, N=200, Recruiting, University of Michigan Rogel Cancer Center | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    9d
    Integration of Single-Cell RNA Sequencing and Machine Learning to Identify and Validate Prognostic Genes With Lymph Node Metastasis and Immune Cell Signatures in Lung Adenocarcinoma. (PubMed, FASEB J)
    Moreover, we demonstrated that FURIN accelerated lymphatic metastasis and lymphangiogenesis in vitro. In this paper, we identified LUAD prognostic genes with LNM and immune cell signatures, emphasized treating LUAD patients according to LNM- and immune cell-related risk scores, and provided novel ideas on how to improve poor prognosis and develop targeted therapy for LUAD.
    Journal • IO biomarker
    |
    FURIN (Furin, Paired Basic Amino Acid Cleaving Enzyme) • KYNU (Kynureninase)
    10d
    NanoGSkin/CB/2019: Study of an Artificial Human Skin Medicine for Patients With Basal Cell Carcinoma Undergoing Reconstructive Surgery. (2024-515235-29-00)
    P1/2, N=15, Recruiting, Red Andaluza De Diseno Y Traslacion De Terapias Avanzadas Fundacion Publica Andaluza Progreso Y Salud | Not yet recruiting --> Recruiting
    Enrollment open
    15d
    Ber-EP4 Expression and Staining Patterns in Cutaneous Basal Cell Carcinoma: A Clinicopathological Study From a Vietnamese Cohort. (PubMed, Am J Dermatopathol)
    Ber-EP4 is a highly sensitive immunohistochemical marker for cutaneous BCC, showing predominantly diffuse expression across diverse clinicohistologic contexts. However, reduced expression in ulcerated tumors and the presence of nondiffuse staining patterns highlight potential diagnostic pitfalls, particularly in superficially sampled lesions. These findings underscore the need for cautious interpretation and integrated histomorphological and immunohistochemical assessment to ensure diagnostic accuracy.
    Journal
    |
    EPCAM (Epithelial cell adhesion molecule)
    20d
    The Purpose of This Study is to Evaluate the Safety and Efficacy of D-MNA in Adult Patients With Nodular Basal Cell Carcinoma (clinicaltrials.gov)
    P2, N=90, Completed, SkinJect, Inc. | Recruiting --> Completed | N=60 --> 90 | Trial completion date: Jun 2025 --> Mar 2026 | Trial primary completion date: Feb 2025 --> Mar 2026
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    |
    doxorubicin hydrochloride
    22d
    Multiplexed Immunofluorescent Characterization of T-Cell and Myeloid Cell Populations Reveals Histologic Subtype Differences Within the Immunosuppressive Landscape of Human Basal Cell Carcinoma. (PubMed, J Cutan Pathol)
    The association of infiltrative BCC with a more immunosuppressed microenvironment may contribute to more aggressive biological behavior. Overall, these data demonstrate a method to determine T cell and myeloid profiles in fixed FFPE skin tumor tissues that can identify subtle immune profile differences.
    Journal
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD163 (CD163 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • FOXP3 (Forkhead Box P3) • CD1C (CD1c Molecule)
    23d
    RELI: Real-world Evaluation of the Implementation of LC-OCT in Daily Clinical Practice (clinicaltrials.gov)
    P=N/A, N=297, Not yet recruiting, Maastricht University Medical Center
    New trial • HEOR • Real-world evidence
    23d
    LEAH: Cohort Evaluation of Body Fluids Early Detection of Cancer in High-risk Individuals (clinicaltrials.gov)
    P=N/A, N=5909, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting --> Recruiting
    Enrollment open
    |
    TP53 (Tumor protein P53) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • STK11 (Serine/threonine kinase 11) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • POLE (DNA Polymerase Epsilon) • RUNX1 (RUNX Family Transcription Factor 1) • BAP1 (BRCA1 Associated Protein 1) • ETV6 (ETS Variant Transcription Factor 6) • MLH1 (MutL homolog 1) • CDK4 (Cyclin-dependent kinase 4) • MSH2 (MutS Homolog 2) • SMAD4 (SMAD family member 4) • CDH1 (Cadherin 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • POLD1 (DNA Polymerase Delta 1) • RAD51C (RAD51 paralog C) • CEBPA (CCAAT Enhancer Binding Protein Alpha) • RAD51D (RAD51 paralog D) • DDX41 (DEAD-Box Helicase 41) • GATA2 (GATA Binding Protein 2) • DICER1 (Dicer 1 Ribonuclease III) • FLCN (Folliculin) • PRSS1 (Serine Protease 1) • SDHD (Succinate Dehydrogenase Complex Subunit D) • TXNIP (Thioredoxin Interacting Protein) • ANKRD26 (Ankyrin Repeat Domain Containing 26) • BMPR1A (Bone Morphogenetic Protein Receptor Type 1A) • HOXB13 (Homeobox B13)
    |
    TP53 mutation • PTEN deletion
    26d
    LANCE: FLASH Radiotherapy for Skin Cancer (clinicaltrials.gov)
    P=N/A, N=60, Active, not recruiting, Centre Hospitalier Universitaire Vaudois | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> May 2026 | Trial primary completion date: Sep 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date